The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy.
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
An evaluation of efficacy, as measured by progression-free survival (PFS) assessed by independent review and overall survival (OS), of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy in patients with advanced HER2+ breast cancer who have received prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine in the neoadjuvant, adjuvant, or metastatic setting, and who have received at least one, and no more than three, lines of therapy in the metastatic setting.
HER-2 Positive Breast CancerMetastatic NeoplasmCapecitabineGemcitabineVinorelbineTrastuzumab
You can join if…
Open to people ages 18 years and up
Histologically-proven metastatic or locally-advanced relapsed/refractory HER2+ breast cancer based on the most recently available tumor biopsy collected from the patient.Tumors may be estrogen receptor (ER)/progesterone receptor (PR) positive or negative.
Prior treatment with pertuzumab, trastuzumab, and ado-trastuzumab emtansine in the neoadjuvant, adjuvant, or metastatic setting. Prior radiotherapy, hormonal therapies,and other anti-HER2 therapies are allowed.
Prior treatment with at least one, and no more than three, lines of therapy in the metastatic setting. Patients must have progressed on or following, the most recent line of therapy.
Resolution of all chemotherapy or radiation-related toxicities to ≤ Grade 1
Life expectancy ≥ 12 weeks
Acceptable laboratory parameters
Women of childbearing potential must have negative pregnancy test performed within 7 days of randomization and on the first day of treatment. All subjects must agree to use an effective form of contraception for the duration of study treatment and for 7 months after the last dose of study drug
You CAN'T join if...
Known, untreated brain metastasis. Patients with signs or symptoms of brain metastasis must have a CT or MRI performed within 4 weeks prior to randomization to specifically exclude the presence of radiographically-detected brain metastases
History of uncontrolled seizures within 6 months of randomization
History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation
History of clinically significant cardiovascular disease
Clinically-significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation
Any condition that would be a contraindication to receiving trastuzumab as described in the approved local label or a condition that would prevent treatment with the physician's choice of chemotherapy
University of California, San Francisco Helen Diller Family Comprehensive Cancer Centeraccepting new patients San Francisco, California, 94115, USA
US Davis Medical Center - UC Davis Comprehensive Centeraccepting new patients Sacramento, California, 95817, USA
Stanford University Medical Centeraccepting new patients Stanford, California, 94305, USA
Kaiser Permenente Medical Centeraccepting new patients Vallejo, California, 94589, USA
Pacific Cancer Medical Center, Incaccepting new patients Anaheim, California, 92801, USA
East Valley Hematology And Oncologyaccepting new patients Burbank, California, 91505, USA
Long Beach Memorial Medical Centeraccepting new patients Long Beach, California, 90806, USA
Hao Wei Zhang, MD, Incaccepting new patients Los Angeles, California, 90033, USA
Sharp Memorial Hospitalaccepting new patients San Diego, California, 92123, USA
Central Coast Medical Oncologyaccepting new patients Santa Maria, California, 93454, USA